ArticleEULAR rheumatology open2026
Risk of nonmelanoma skin cancer in patients with psoriatic arthritis and according to bDMARD treatment-a cohort study from the Nordic Arthritis Research Collaboration.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate if psoriatic arthritis (PsA) itself and if biological disease-modifying antirheumatic drugs (bDMARDs) used in PsA are associated with increased risks of nonmelanoma skin cancer (NMSC). Methods: From nationwide health and clinical rheumatology registers in 4 Nordic countries, we identified patients with PsA who between 2010 and 2021 started a: (i) tumour necrosis factor inhibitor (TNFi), or (ii) non-TNFi bDMARD, or were (iii) b/targeted synthetic (ts)DMARD naïve. For Sweden and Denmark, we identified incident patients with PsA (2010-2021) and corresponding general population (GP) comparator subjects. Using ever-treated follow-up, incidence rates and adjusted hazards ratios (aHRs) with 95% CIs were calculated for NMSC overall, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC), respectively. Results: We identified 619 NMSCs among incident patients with PsA (n = 23,553). We observed 221 NMSCs in TNFi-treated (n = 9999), 34 NMSCs in non-TNFi bDMARD-treated (n = 2200), and 433 NMSCs in b/tsDMARD-naïve (n = 19,089) PsA. The aHR of NMSC for incident PsA vs GP was 1.20 (1.11-1.31). Pooled aHRs for NMSC overall were 1.24 (1.03-1.50) with TNFi and 1.11 (0.75-1.63) with non-TNFi bDMARDs vs b/tsDMARD-naïve PsA. Corresponding aHRs of BCC were 1.21 (0.93-1.58) for TNFi and 0.85 (0.42-1.69) for non-TNFi bDMARDs, whereas aHRs for SCC were 1.46 (0.84-2.56) and 2.37 (0.95-5.90). Conclusions: Increased risks of NMSC (SCC in particular) were found in patients with PsA compared with the GP. Compared with b/tsDMARD-naïve PsA, TNFi was associated with an increased risk of NMSC overall, whereas a nonsignificantly increased risk of SCC was seen for non-TNFi bDMARDs. However, causality between bDMARD use and NMSC in PsA remains uncertain.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.